

Title/authors	Presentation Type	Session date and time (ZONE)	Download Presentation
<b>Doravirine/Islatravir 100/0.75mg once daily compared to Bictegravir/Entricitabine/Tenofovir Alafenamide (B/F/TAF) as initial HIV-1 treatment: 48 week results from a double-blind phase 3 trial</b> <a href="#">Rockstroh JK</a> , Paredes R, Cahn P, Molina J-M, Sokhela S, Hinebrosa F, Kassim S, Valencia Ortega E, Cunningham D, Ghosn J, Bogner JR, Gatanaga H, Asante-Appiah E, Zhang Y, Klopfer SO, Eves K, Pisculli ML, Squires K, Correll TA	Oral Presentation	Mon, 24 July 10:30-11:30 AEST	<a href="#">↓</a>
	Plain Language Summary	Mon, 24 July 10:30-11:30 AEST	<a href="#">↓</a>
<b>Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018)</b> <a href="#">McComsey GA</a> , Molina J-M, Mills AM, Rockstroh JK, Walmsley S, Mngqibisa R, Braun D, Zhou Y-P, Klopfer SO, Grandhi A, Su F-H, Fox MC, Kim AJ, Correll TA	Oral Presentation	Tues, 25 July 14:45-15:45 AEST	<a href="#">↓</a>
<b>Renal safety parameters after switch to doravirine/islatravir (DOR/ISL 100/0.75mg) once-daily: week 48 results from 2 randomized, active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018)</b> Post FA, Molina J-M, Mills AM, Lacombe K, Rockstroh JK, McMullan CJ, Zhou Y-P, Grandhi A, Su F-H, Kim AJ, Fox MC, Correll TA	Poster	Mon, 24 July 12:00-13:00 AEST	<a href="#">↓</a>
<b>Doravirine Resistance Patterns Identified through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials</b> Orkin C, Kuritzkes D, Katlama C, Su F-H, Teal V, Plank RM, Lahoulou R, Asante-Appiah E	Poster	Tues, 25 July 12:00-13:00 AEST	<a href="#">↓</a>
<b>Incidence of infections across islatravir clinical development programs</b> K Squires K, Correll TA, Robertson MN, Klopfer SO, Hwang PMT, Zhou Y-P, Martin E, Rhee E	ePoster	Sun, 23 July Throughout Congress	<a href="#">↓</a>
<b>Interpretation of doravirine resistance by algorithm in antiretroviral-naive patients with HIV in Haiti</b> Pierre S, Wu J, Campo R, Asante-Appiah E, Liautaud B, Koenig S, Pape JW	ePoster	Sun, 23 July Throughout Congress	<a href="#">↓</a>
<b>Islatravir (MK-8591) has no meaningful effect on the pharmacokinetics of atorvastatin and metformin following co-administration</b> McCrea J, Patel M, Liu Y, Litovsky A, Witter R, Vargo R, Aubrey Stoch S, Iwamoto M, Matthews RP	ePoster	Sun, 23 July Throughout Congress	<a href="#">↓</a>
<b>Assessment of transmitted drug resistance mutations to doravirine: a survey in Argentina</b> Cecchini D, Cassetti I, Scarnato F, Fiori A, Nuevo J, Villaverde C, Sucari A, Torroija MC, Bugarín G, Lopardo G	ePoster	Sun, 23 July Throughout Congress	<a href="#">↓</a>